Guillain-Barré syndrome.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Disease-a-month : DM

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.disamonth.2010.02.003PMID 20493301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous immunoglobulin for Guillain-Barré syndrome.

  2006cited by this paper
• Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome

  2005cited by this paper
• Residual neuropathy in long-term population-based follow-up of Guillain–Barré syndrome

  2005cited by this paper
• Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy

  2005cited by this paper
• Antecedent infections in Fisher syndrome

  2005cited by this paper
• Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome?

  2005cited by this paper
• [Guillain-Barré syndrome].

  2005cited by this paper
• HLA class II alleles are not a general susceptibility factor in Guillain–Barré syndrome

  2005cited by this paper
• Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome

  2005cited by this paper
• Electrophysiological signs of permanent axonal loss in a follow‐up study of patients with Guillain–Barré syndrome

  2005cited by this paper
• Severity of GuillainBarr syndrome is associated with Fc? Receptor III polymorphisms

  2005cited by this paper
• Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations

  2005cited by this paper
• The Guillain-Barré syndrome: a true case of molecular mimicry.

  2004cited by this paper
• Neurophysiological and immunohistochemical studies on Guillain-Barre syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission.

  2004cited by this paper
• An anti‐ganglioside antibody‐secreting hybridoma induces neuropathy in mice

  2004cited by this paper
• Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome.

  2004cited by this paper
• Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system

  2004cited by this paper
• Electron microscopic studies on ordinary and hyperacute experimental allergic encephalomyelitis

  2004cited by this paper
• Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2004cited by this paper
• Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996

  2004cited by this paper
• Blood gammadelta T cells, Campylobacter jejuni, and GM1 titers in Guillain-Barré syndrome.

  2004cited by this paper
• Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

  2004cited by this paper
• Acute motor axonal neuropathy after Mycoplasma infection

  2004cited by this paper
• Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy

  2004cited by this paper
• Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome.

  2004cited by this paper
• The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

  2004cited by this paper
• Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.

  2004cited by this paper
• Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.

  2004cited by this paper
• Physical training and fatigue, fitness, and quality of life in Guillain–Barré syndrome and CIDP

  2004cited by this paper
• Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.

  2004cited by this paper
• Intravenous immunoglobulin in autoimmune neuromuscular diseases.

  2004cited by this paper
• Differential Distribution of HLA-DQβ/DRβ Epitopes in the Two Forms of Guillain-Barré Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQβ Epitopes Associated with Susceptibility to and Protection from AIDP1

  2003cited by this paper
• Guillain-Barré syndrome

  2003cited by this paper
• Binding of immunoglobulin G antibodies in Guillain–Barré syndrome sera to a mixture of GM1 and a phospholipid: Possible clinical implications

  2003cited by this paper
• A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

  2003cited by this paper
• Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy.

  2003cited by this paper
• Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy

  2003cited by this paper
• CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barré and Fisher syndromes.

  2003cited by this paper
• GalNAc-GD1a in human peripheral nerve

  2003cited by this paper
• Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.

  2003cited by this paper
• Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome

  2003cited by this paper
• Subacute inflammatory demyelinating polyneuropathy

  2003cited by this paper
• Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons

  2003cited by this paper
• Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes

  2003cited by this paper
• The refractory period of transmission is impaired in axonal Guillain–Barré syndrome

  2003cited by this paper
• Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera.

  2003cited by this paper
• Localization of major gangliosides in the PNS: implications for immune neuropathies.

  2002cited by this paper
• An unusual case of Behçet’s disease presenting with bilateral internal carotid artery occlusion

  2002cited by this paper
• Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS.

  2002cited by this paper
• Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China

  2002cited by this paper
• Peripheral neuropathies and anti-glycolipid antibodies.

  2002cited by this paper
• Autonomic function in demyelinating and axonal subtypes of Guillain–Barré syndrome

  2002cited by this paper
• Long-term impact on work and private life after Guillain-Barré syndrome.

  2002cited by this paper
• Campylobacter jejuni from Patients with Guillain-Barré Syndrome Preferentially Expresses a GD1a-Like Epitope

  2002cited by this paper
• Preceding infections, immune factors, and outcome in Guillain–Barré syndrome

  2001cited by this paper
• Gastroenteritis-associated Guillain–Barré syndrome on the Caribbean Island Curaçao

  2001cited by this paper
• Epidemiology of the Guillain-Barré syndrome

  2001cited by this paper
• Animal model of axonal Guillain‐Barré syndrome induced by sensitization with GM1 ganglioside

  2001cited by this paper
• Sodium channel inactivation in an animal model of acute quadriplegic myopathy

  2001cited by this paper
• GUILLAIN-BARRE SYNDROME IN ORGAN AND BONE MARROW TRANSPLANT PATIENTS

  2001cited by this paper
• Development of Spontaneous Autoimmune Peripheral Polyneuropathy in B7-2–Deficient Nod Mice

  2001cited by this paper
• Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal.

  2001cited by this paper
• Childhood Guillain-Barré Syndrome: Clinical and Electrophysiologic Features Predictive of Outcome

  2001cited by this paper
• Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies.

  2001cited by this paper
• Miller Fisher syndrome and Haemophilus influenzae infection

  2001cited by this paper
• Early electrodiagnostic findings in Guillain-Barré syndrome.

  2001cited by this paper
• Mild Guillain-Barré syndrome.

  2001cited by this paper
• Guillain-Barré syndrome: an Italian multicentre case-control study

  2000cited by this paper
• Corticosteroids for treating Guillain-Barré syndrome.

  2000cited by this paper
• Axonal Guillain‐Barré syndrome: Relation to anti‐ganglioside antibodies and Campylobacter jejuni infection in Japan

  2000cited by this paper
• Anti-PMP22 antibodies in patients with inflammatory neuropathy.

  2000cited by this paper
• Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain‐Barré syndrome: A reappraisal

  1999cited by this paper
• Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection

  1999cited by this paper
• Pathogenesis of Guillain-Barré syndrome.

  1999cited by this paper
• Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates.

  1999cited by this paper
• Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

  1999cited by this paper
• Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome

  1999cited by this paper
• Anti‐GD1a antibody is associated with axonal but not demyelinating forms of Guillain‐Barré syndrome

  1999cited by this paper
• Axonal involvement at the common entrapment sites in Guillain‐Barré syndrome with IgG anti‐GM1 antibody

  1999cited by this paper
• Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barré syndrome

  1999cited by this paper
• Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

  1999cited by this paper
• Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange

  1999cited by this paper
• Genetic contribution of the tumor necrosis factor region in guillain‐barré syndrome

  1998cited by this paper
• Epidemiological study of Guillain-Barré syndrome in south east England

  1998cited by this paper
• HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome

  1998cited by this paper
• Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections.

  1998cited by this paper
• The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

  1998cited by this paper
• Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome

  1998cited by this paper
• The distribution of CD1 molecules in inflammatory neuropathy.

  1998cited by this paper
• Loss of electrical excitability in an animal model of acute quadriplegic myopathy

  1998cited by this paper
• T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome.

  1997cited by this paper
• Patterns of recovery in the Guillain-Barre syndromes

  1997cited by this paper
• The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons.

  1997cited by this paper
• Electrodiagnostic studies in the Dutch multicentre Guillain-Barré study: a review.

  1997cited by this paper
• Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome.

  1997cited by this paper
• Residual health status after Guillain-Barré syndrome.

  1997cited by this paper
• Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome.

  1997cited by this paper
• Appropriate number of plasma exchanges in Guillain‐Barré syndrome

  1997cited by this paper
• Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome.

  1997cited by this paper
• 'Intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome'.

  1997cited by this paper

• No citing papers are available for this paper.